Resources & Links

Resources

For healthcare professionals

Prescribing Information Dosing & Administration Brochure Product Characteristics Alnylam Assist Brochure

Billing & Coding Guide for Hospitals Billing & Coding Guide for Physicians Access and Reimbursement Guide Mixed Phenotype (hATTR) Sample Letter of Medical Necessity

ATTR-CM

NEJM article: Vutrisiran in Patients With ATTR-CM ATTR-CM Clinical Overview ATTR-CM Coverage Checklist ATTR-CM 1L Sample Letter of Medical Necessity ATTR-CM 2L Sample Letter of Medical Necessity ATTR-CM Concomitant Sample Letter of Medical Necessity

hATTR-PN

hATTR-PN Clinical Overview hATTR-PN Coverage Checklist hATTR-PN Letter of Medical Necessity

Choose a Start Form

Electronic Start Form

Download Start Form

Educational resources for patients

Alnylam Assist® Brochure for Patients

ATTR-CM

AMVUTTRA Treatment Brochure Caregiver Brochure

hATTR-PN

AMVUTTRA Treatment Brochure Caregiver Brochure

ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Educational videos for healthcare professionals

AMVUTTRA's Mechanism of Action

See how treatment with AMVUTTRA led to a rapid knockdown of TTR protein in serum.

Watch the video

Administering AMVUTTRA

This instructional video for healthcare professionals provides walk-through steps for AMVUTTRA administration.

Watch the video

Patient Video

Learn about Randy's experience with wtATTR. In this video, he walks through his symptoms and how they affect his everyday life.

Watch the video

Stay informed

Receive more information about AMVUTTRA.

Connect with us

Find a treatment center

Locate a treatment center close to your patients.

View the directory

Up next: Search the AMVUTTRA Treatment Center Directory

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

For patients